Article

Cellares and the University of Wisconsin School of Medicine and Public Health have expanded their partnership to advance clinical manufacturing of the university's CRISPR-edited GD2 CAR-T therapy for solid tumors. The collaboration will utilize Cellares' automated platforms to support regulatory submissions and improve manufacturing processes for pediatric and adult patients. The GD2 CAR-T program targets solid tumors like high-grade gliomas with potential applications for neuroblastoma and melanoma.